The most extensively studied for targeted immunotherapy in lung cancer include inhibitory receptors cytotoxic T-lymphocyte-associate protein 4 (CTLA4), programmed death protein 1 (PD1), and programmed death ligand 1 (PD-L1) [176]. The gene discussed is CTLA4; the disease is lung carcinoma.